The Journal of the Korean Rheumatism Association 2010; 17(1): 86-92
Published online March 30, 2010
© Korean College of Rheumatology
이지선ㆍ방소영ㆍ유대현ㆍ변영상ㆍ박수역ㆍ김태환
한양대학교 의과대학 내과학교실, 류마티스병원 류마티스내과
Correspondence to : Tae Hwan Kim
Ankylosing spondylitis is a disease that shows a young age of onset (less than 40 years old), inflammatory back pain, sacroiliitis and a strong association with HLA-B27. Yet some recently reported cases have presented with a late age of onset (more than 55 years old), atypical clinical presentations and a low response to NSAIDs, and this has also been named late onset spondyloarthropathy (LOSPA). As compared with early onset spondyloarthropathy (EOSPA), the LOSPA patients more frequently suffer with combined peripheral arthritis and inflammatory systemic symptoms and a high ESR and CRP level, but they lack the typical axial symptoms. Yet there have been few reports about late onset ankylosing spondylitis (LOAS). The previous cases of LOSPA and LOAS were managed with NSAIDs, steroids, methotrexate and sulfasalazine, but none were managed with TNF antagonists. LOAS is rare and difficult for management because of the patients' older age and the lack of experiences with this malady, so we report here on the four cases of LOAS that were successfully treated by TNF antagonists.
Keywords Late onset, Ankylosing spondylitis, TNF antagonist
The Journal of the Korean Rheumatism Association 2010; 17(1): 86-92
Published online March 30, 2010
Copyright © Korean College of Rheumatology.
이지선ㆍ방소영ㆍ유대현ㆍ변영상ㆍ박수역ㆍ김태환
한양대학교 의과대학 내과학교실, 류마티스병원 류마티스내과
Ji Sun Lee, So-young Bang, Dae-Hyun Yoo, Young Sang Byun, Soo Yuk Park, Tae Hwan Kim
Departments of Internal Medicine Division of Rheumatology, The Hospital for Rheumatic Diseases, Hanyang University College of Medicine, Seoul, Korea
Correspondence to:Tae Hwan Kim
Ankylosing spondylitis is a disease that shows a young age of onset (less than 40 years old), inflammatory back pain, sacroiliitis and a strong association with HLA-B27. Yet some recently reported cases have presented with a late age of onset (more than 55 years old), atypical clinical presentations and a low response to NSAIDs, and this has also been named late onset spondyloarthropathy (LOSPA). As compared with early onset spondyloarthropathy (EOSPA), the LOSPA patients more frequently suffer with combined peripheral arthritis and inflammatory systemic symptoms and a high ESR and CRP level, but they lack the typical axial symptoms. Yet there have been few reports about late onset ankylosing spondylitis (LOAS). The previous cases of LOSPA and LOAS were managed with NSAIDs, steroids, methotrexate and sulfasalazine, but none were managed with TNF antagonists. LOAS is rare and difficult for management because of the patients' older age and the lack of experiences with this malady, so we report here on the four cases of LOAS that were successfully treated by TNF antagonists.
Keywords: Late onset, Ankylosing spondylitis, TNF antagonist
Vitaly Omelchenko, M.D., Elena Letyagina, M.D., Maxim Korolev, M.D.
J Rheum Dis 2024; 31(4): 253-256Bon San Koo, M.D., Ph.D., Miso Jang, M.D., Ph.D., Ji Seon Oh, M.D., Ph.D., Keewon Shin, Ph.D., Seunghun Lee, M.D., Ph.D., Kyung Bin Joo, M.D., Ph.D., Namkug Kim, Ph.D., Tae-Hwan Kim, M.D., Ph.D.
J Rheum Dis 2024; 31(2): 97-107Inbeom Kwon, M.D., Nayeon Choi, M.S., Ji Hui Shin, M.S., Seunghun Lee, M.D., Ph.D., Bora Nam, M.D.,Ph.D., Tae-Hwan Kim, M.D., Ph.D.
J Rheum Dis 2024; 31(1): 41-48